Pharmacovigilance Audit Training

What do you need to know?

16-17 February 2020

Fairmont Nile City Hotel, Cairo Egypt

Supported By:


AMGEN BAUSCH Health Amoun

SCOPE OF TRAINING

This training course will describe internationally accepted principles, practical approaches, and regulatory expectations for a company’s pharmacovigilance quality management system. The topics will cover organizational structure, responsibilities, processes and resources required for the pharmacovigilance (PV) system and its quality system based on ISO and ICH requirements. The course is designed for pharmaceutical professionals in the early phases of developing and improving a quality system. This includes what it means to be inspection ready and how to respond in and after an inspection. As well as a thorough theoretical grounding in the subject, there will be practical exercises such as how to write a good quality SOP and how to conduct and perform during an inspection or audit. All of this will be adapted to the current regulatory environment in Egypt.

WHAT WILL THE DELEGATES EXPECT TO LEARN IN THIS COURSE?

At the conclusion of this course, we aim for delegates to be able to:

  • Understand features of a quality system which underpin all GXP activities and differences between a quality management and pharmacovigilance audit?
  • Describe how to design, develop, and manage a quality system related to your pharmacovigilance system which is fit for purpose in Egypt in the context of a global pharmacovigilance quality system.
  • Explain and describe the components of pharmacovigilance system master file and how this document provides both a foundation for the quality system but also acts as an important tool for inspection readiness.
  • Analyse and improve processes for the development, maintenance, and quality oversight of pharmacovigilance SOPs and pharmacovigilance related documents, including Pharmacovigilance Agreements all phases of the life cycle of a medicine
  • Better arrange plans for risk-based audits of the quality system including the variety of different audits needed such as those for business partners and vendors.
  • Organise preparations are for audits and inspections, preparing responses and corrective and preventive action plans.

WHO WILL BENEFIT FROM ATTENDING?

This program is designed for pharmaceutical and regulatory professionals involved in:

  • Quality assurance and compliance of the pharmacovigilance system
  • Pharmacovigilance auditors
  • Qualified persons for pharmacovigilance and their deputies
  • Pharmacovigilance personnel responsible for compliance, training, pharmacovigilance agreements, and/or pharmacovigilance quality documents

VENUE:

Fairmont Nile City Hotel

FEES:

For Local Participants:
1-2 delegates : 400 USD
3-4 Delegates: 300 USD
5+ delegates: 250 USD
For International Participants:
1-2 delegates: 600 USD
3+ delegates: 500 USD

 

OUR EXPERTS

Larry Thomas

Larry Thomas

Director Global System Audits
Bayer U.S.

Dr. Brian Edwards

Dr. Brian Edwards

MD MRCP, Principal Consultant
Pharmacovigilance & Drug Safety, NDA Regulatory Science, UK

Dr. Hadir Rostom

Dr. Hadir Rostom

President
ISoP Egypt Chapter

Yasmeen Gwely

Yasmeen Gwely

Regional Head Patient Safety Quality Assurance – Middle East & Africa
Novartis Pharma

Marianne Mounir

Marianne Mounir

Pharmacovigilance country operation Lead
MSD, Egypt, Libya, Sudan, Yemen and Central African sub-region

Dr. Ahmed Hegazy

Dr. Ahmed Hegazy

Consultant Pharmacovigilance, Managing Director
PVigilant Health

Debra Hayman

Debra Hayman

Senior Quality Country Cluster Lead
Roche

Sandrine Valiere

Sandrine Valiere

Global PV Audit/Inspection Readiness Head
Sanofi